Selective insect-targeted small molecules for safer pest control
A library of 15-20 naturally-inspired small molecules with selective toxicity to insect cells and no activity in human cells. These compounds activate insect caspases to trigger apoptosis, outperforming benchmark insecticides while avoiding classical toxicological chemical groups.
Overview
This offering comprises a curated library of 15-20 small molecules developed through medicinal chemistry optimization of a natural product scaffold. The compounds display selective toxicity toward insect cells while remaining inactive against human cells, addressing a critical safety challenge in pesticide development. By activating insect-specific caspase pathways and inducing apoptosis, the molecules demonstrate potency that exceeds conventional benchmark insecticides. Importantly, the chemical structures avoid functional groups classically associated with toxicological risks, supporting a more favorable safety profile.
Technical specifications
Key features:
- Selective cytotoxicity demonstrated in insect cell lines with no observable toxicity in human cell models
- Naturally-inspired scaffold refined through structure-activity relationship studies to improve selectivity
- Novel mechanism of action through activation of insect caspases, triggering programmed cell death (apoptosis)
- Superior potency compared to benchmark insecticides in head-to-head testing
- Clean toxicological profile with no classical toxicophores (chemical groups associated with adverse events)
- Defined chemical space of 15-20 derivatives enabling structure-property optimization
Applications:
- Crop protection and agricultural pest management
- Vector control for insect-borne disease prevention
- Development of next-generation bioinspired insecticides
- Starting point for further lead optimization and formulation development
Technology readiness level
The molecules have been validated in cell-based assays demonstrating selective insect cell toxicity and human cell safety. The caspase-mediated apoptosis mechanism has been confirmed, and comparative potency testing against benchmark insecticides has been completed. The compounds are at an early-to-mid stage of preclinical development, with opportunities for further optimization, formulation, and in vivo validation studies.
About Universidade do Porto
Universidade do Porto is one of Portugal’s largest public universities, combining comprehensive education with research that engages regional and global industry. A university‑anchored science and technology park links corporate R&D, startups, and faculty labs, offering incubation, workspace and access to shared facilities. Clinical and translational work benefits from co‑location with major teaching hospitals, enabling access to patients, data and regulated studies. Research is supported by competitive European and national funding, including programs of the European Commission and Portugal’s national science foundation. A dedicated technology transfer office manages IP strategy, licensing, industry contracts and startup support to accelerate commercialization.
delivered to your inbox.